| Imaging Mass Spectrometry Society |
Executive Committee |
Dr. Richard R. Drake, PresidentDr. Drake is a Professor in the Department of Cell and Molecular Pharmacology and Experimental Therapeutics at the Medical University of South Carolina and SmartState Endowed Chair in Proteomics. He is an experienced protein biochemist and glycobiologist, with particular expertise in imaging MS of tumor tissues and biomarker discovery from clinical fluids. Dr. Drake received a B.S. from Centre College, Danville, KY, and a Ph.D. from the University of Kentucky, both in Biochemistry and Molecular Biology. Post-doctoral training in glycobiology was done with Alan Elbein at the University of Texas Health Science Center at San Antonio. Current efforts are in the large scale application of N-glycan MS imaging methods developed in his laboratory to prostate, pancreas, liver, and breast tumors. The goal is to develop glycan biomarkers associated with tumor, stroma and immune regions of tumors, in two and three dimensions. |
Dr. Peggi Angel, President-ElectPeggi Angel is currently Assistant Professor at Medical University of South Carolina, where she works on technology advancements in MALDI IMS and application to cardiovascular disease and cancer. Peggi attended graduate school at the University of Georgia’s Complex Carbohydrate Research Center, graduating with a PhD in 2007. Her graduate research was on quantitative proteomics and N-linked glycoproteomics in mammalian development. After a postdoctoral study at Emory University focused on membrane proteomics of fetal alcohol syndrome, she won a competitive Postdoctoral Fellowship with the Systems-based Consortium for Organ Design and Engineering. With the Fellowship, she worked at Vanderbilt University on methods using MALDI IMS for developmental biology and participated in establishing the National Research Resource in Imaging Mass Spectrometry. Peggi has developed IMS methods for increasing sensitivity of protein detection from tissues, analysis and identification of lipids in negative mode at high spatial resolution, metabolomics on tissue and cell culture, targeted protein detection in tissues, proteomics of thin tissue sections, and on-tissue chemistries. |
Dr. Kevin Schey, PresidentDr. Schey is currently Professor of Biochemistry within the Mass Spectrometry Research Center at Vanderbilt University. He also serves as Deputy Director of Research for the NIH Center on Imaging Mass Spectrometry. His research interests lie in the areas of proteomics of aging in ocular tissues, exosome proteomics, and imaging mass spectrometry. He is particularly interested in method development for IMS and applications to diseases of ocular tissues. Dr. Schey received his B.S. in Chemistry from Muhlenberg College in Allentown, PA and his Ph.D. in Analytical Chemistry from Purdue University working under the mentorship of Dr. Graham Cooks. After post-doctoral training at the University of Chicago he began his academic career at the Medical University of South Carolina in Charleston, SC. After 18 years at MUSC, he moved to Vanderbilt University where he directs the Core laboratories in Imaging MS, Proteomics, and small molecule MS. He is on the Editorial Review Board of the Journal of Biological Chemistry and has published over 140 manuscripts. |
Dr. Eric Solon, TreasurerEric Solon, Ph.D., is currently the Treasurer of the Imaging Mass Spectrometry Society and the Senior Director of Pharmacology and ADME at Madrigal Pharmaceuticals. Dr. Solon now directs and supports various preclinical and clinical studies to support the development of Madrigal Pharmaceuticals lead new drug candidate. Before joining Madrigal, Eric was the Senior Director and Fellow of Autoradiography in Pre-Clinical Drug Metabolism and Pharmacokinetics (DMPK) for QPS, LLC. Eric Joined QPS in 2002 as Director and business head of Autoradiography and Animal Resource units. Dr. Solon is an internationally recognized expert in the study of drug tissue distribution at the macro/micro level and has published >25 articles and 4 book chapters. Eric earned his Ph.D. Rutgers Univ.; and MS at Fairleigh Dickinson University while holding various positions in the Pathology Department of the Safety Evaluation Facility for Ciba-Geigy Pharmaceuticals (Novartis). Dr. Solon held various positions in DMPK as well as coordinating ADME studies and all QWBA tissue distribution/ADME studies at DuPont Pharmaceuticals, and Schering-Plough Corporation. He has expertise in managing lab operations, profit center operations, lab animal anatomy, physiology, necropsy & histology, gross pathology, pre-clinical ADME studies, and laboratory and computer validations. He served as President, President-elect, President Ex Officio, Webmaster, Secretary, and Councilor for the Society for Whole-Body Autoradiography (SWBA) and is an active member of the International Isotope Society. |
Dr. Stacy Ho, CommunicationStacy Ho, Ph.D worked at Centers for Disease Control and Prevention (CDC) from 1996 to 1998, where she analyzed human plasma to monitor smoking and second hand smoking within the US population. Following her tenure at CDC, she worked at two CROs: first at MDS Pharma Services (1998 to 2002) as a scientist of Analytical Services, performing pharmaceutical testing and per-formulation and formulation support and later at WIL Research Laboratories, LLC (2002 to 2007) as the manager of Bioanalytical Chemistry before joined Genzyme, a Sanofi company, in 2007. She has a master degree in Organic Chemistry from East Tenseness State University and Ph.D. in Analytical Chemistry from Georgia Institute of Technology. Stacy has authored and co‑authored several journal articles and book chapters. She served as guest editor for Bioanalysis journal special focus issue on tissue analysis in 2012 and edited the eBook entitled “Tissue Analysis for Drug Development” in 2013. She has presented podium talks and poster presentations at national meetings. She has been a member of the Organization Committee for Land O’Lakes Bioanalytical Conference since 2008 and served as the Conference Chair in 2013. She is the current Chair of American Association of Pharmceutical Scientists (AAPS) CRO Focus Group. |
Dr. Christopher R. Anderton, CounselorChris Anderton is currently a staff scientist at the Environmental Molecular Sciences Laboratory (EMSL), which is located on the Pacific Northwest National Laboratory (PNNL) campus. Chris received his BS in chemistry at the University of Colorado at Colorado Springs in 2005. He attained his PhD in chemistry at the University of Illinois at Urbana–Champaign in 2011, under Mary L. Kraft, where his graduate work focused on using secondary ion mass spectrometry (ToF-SIMS and NanoSIMS) in conjunction with atomic force microscopy and scanning electron microscopy for multi-technique correlative analysis of supported lipid membranes. Afterward, he received a US National Research Council Postdoctoral Associateship to work at the National Institute of Standards and Technology under Anne L. Plant, where he studied how eukaryotic cells respond to changes in the physicochemical properties of their extracellular environment, using force microscopy, fluorescence microscopy, and ToF-SIMS. In 2013, he joined the Mass Spectrometry Group at EMSL, where he is now leading the effort in developing new imaging mass spectrometry instrumentation and capabilities to elucidate chemical interactions occurring within microbial communities, soils, and the rhizosphere. In his free time, Chris loves to travel and explore the great outdoors. |
Reid Groseclose, CounselorReid Groseclose is currently a Senior Investigator and GSK Fellow in the Bioimaging group at GlaxoSmithKline. Reid received his B.S. in chemistry from the University of Tennessee in 2004 and his Ph.D. in chemistry from Vanderbilt University in 2009 in the lab of Richard Caprioli, where his work focused on exploring the utility of imaging mass spectrometry and on-tissue proteomics for the analysis and classification of cancerous tissues. He joined GlaxoSmithKline in 2009, where his research interests have centered on the application of imaging mass spectrometry to assess the tissue distribution of drugs and their metabolites. His group is particularly interested in using IMS to quantify the localized tissue concentration of drug candidates and investigating mechanisms of pharmacology and safety. |
Stefan Linehan, APAC LiaisonStefan Linehan has nearly twenty years of experience in the ADME (DMPK) and Toxicology areas, with more recently an involvement in the Discovery field. He is also well known for his development and expertise with the 3D cryo-imaging and autoradiography techniques. Linehan’s most recent position was the Director of North American and Head of Japan at ImaBiotech, where he was responsible for overseeing and directing the operations in North America, including business development as well as establishing and building a team responsible for selling mass spectrometry imaging (MSI) services out of the ImaBiotech Greater Boston, MA facility. Linehan has also held previous positions at inviCRO, XenoBiotic Laboratories, and WIL Research Laboratories; where he set up and managed the quantitative whole body autoradiography (QWBA) capabilities and conducted mass balance/pharmacokinetic studies. He has also worked at Wyeth Pharmaceuticals, where he developed the 3D cryo-imaging techniques and conducted regulated tissue distribution, mass balance, and pharmacokinetic studies. Linehan received his Masters in Clinical Biochemistry from Griffith University in Queensland, Australia and his Bachelors in Biology from Colorado State University, CO. He has also lived overseas in both Australia and Japan, which has provided him with a deep understanding of business and culture on a global scale. Stefan Linehan was the last President of the Society for Whole Body Autoradiography (SWBA) and has held multiple Executive Committee Officer Positions since 2003. He is a co-founder and past Executive Committee Councilor for the Imaging Mass Spectrometry Society (IMSS). |
